Ion Channel Modulators
•7 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (7)
| Company | Market Cap | Price |
|---|---|---|
|
VRTX
Vertex Pharmaceuticals Incorporated
Vertex's pain program includes NaV channel modulators (NaV1.8/NaV1.7), a distinct ion channel modulator category.
|
$109.29B |
$425.63
+1.37%
|
|
NBIX
Neurocrine Biosciences, Inc.
Osavampator is a potent AMPA receptor modulator, aligning with Ion Channel Modulators as a mechanism class.
|
$14.20B |
$143.19
+3.73%
|
|
XENE
Xenon Pharmaceuticals Inc.
Xenon's lead asset XEN1101 is a selective Kv7 potassium channel opener, mapping to Ion Channel Modulators.
|
$3.22B |
$41.92
-1.75%
|
|
BHVN
Biohaven Ltd.
BHVN's Kv7 ion channel modulation platform (BHV-7000) and TRPM3 antagonist (BHV-2100) position the company in Ion Channel Modulators, a key neuroscience/pain modality.
|
$1.76B |
$17.20
-1.06%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Lead asset RAP-219 is a small molecule AMPAR NAM targeting neuronal ion channels, i.e., ion channel modulators.
|
$1.06B |
$28.89
+7.48%
|
|
MIST
Milestone Pharmaceuticals Inc.
Etripamil is an ion channel modulator (calcium channel blocker) delivered as a nasal spray.
|
$102.65M |
$1.93
+2.39%
|
|
CALC
CalciMedica, Inc.
CalciMedica's lead candidate Auxora is a CRAC channel inhibitor, i.e., an ion channel modulator.
|
$41.36M |
$2.96
-1.00%
|
Loading company comparison...
Loading industry trends...
Loading research report...
